Test/Investigation
Anti Xa/DOAC assay/Heparin monitoring/Dabigatran
Site(s) or Laboratory offering Test/Investigation
JPUH , NNUH, QEH
Units
iu/ml (Xa), ng/ml(DOAC + dabigatran)
Indications
Assessment of anticoagulation
Comments/Precautions
For therapeutic monitoring of Low molecular weight heparin, unfractionated heparin, and direct oral anticoagulants. Please provide details of anticoagulants, if patient is on any.
Storage conditions and sample stability between collection and transport to Lab
room temperature
Ideal sample age for accurate results/Maximum acceptable sample age (at the time of analysis)
4 hours
Sample type
Citrate (1:9)
Turnaround times (TAT) Urgent/Routine/GP or OPD
4 hours, if sample received in laboratory between 9am and 3pm; otherwise next working day.
Reference intervals (adult unless stated)
Xa treatment :0.5-1, prophylactic : 0.2-0.4.
Unfractionated heparin monitoring: treatment dose 0.3-0.7 iu/ml.
Rivaroxaban stoke prevention peak: 184-343ng/ml and trough 12-137ng/ml. Rivaroxaban VTE treatment peak: 189-419ng/ml. trough 6-87ng/ml.
Apixaban stoke prevention peak: 91-321ng/ml and trough 41-230ng/ml.
Apixaban VTE treatment peak: 59-302ng/ml. trough 22-177ng/ml.
Edoxaban stoke prevention peak: 125-245ng/ml and trough 19-62ng/ml.
Edoxaban VTE treatment peak: 149-317ng/ml. trough 10-39ng/ml.
Dabigatran stoke prevention peak: 117-275ng/ml and trough 61-143ng/ml.
Dabigatran VTE treatment peak: 117-275ng/ml, trough 39-95ng/ml.
If UKAS Accredited Test indicate at which site
Yes: NNUH ,QEH, JPH